- Home
- PLRX vs ATYR Comparison
PLRX vs ATYR Comparison
Compare PLRX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PLRX | ATYR |
|---|---|---|
| Founded | 2015 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.3M | 79.2M |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PLRX | ATYR |
|---|---|---|
| Price | $1.31 | $0.73 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 11 | 6 |
| Target Price | $3.79 | ★ $8.75 |
| AVG Volume (30 Days) | 945.1K | ★ 2.0M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $190,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.10 | $0.64 |
| 52 Week High | $13.46 | $7.29 |
Technical Indicators
Market Signals| Indicator | PLRX | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 48.45 | 42.81 |
| Support Level | $1.20 | $0.71 |
| Resistance Level | $1.36 | $0.76 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 64.71 | 20.29 |
Price Performance
Historical ComparisonAbout PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
About ATYR aTyr Pharma Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.